Tumour-promoting role of SOCS1 in colorectal cancer cells

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Tobelaim, William S ^a   Beaurivage, Claudia ^a   Champagne, Audrey ^a   Pomerleau, Véronique ^a   Simoneau, Aline ^a   Chababi, Walid ^a   Yeganeh, Mehdi ^a   Thibault, Philippe ^a   Klinck, Roscoe ^a   Carrier, Julie C ^a   Ferbeyre, Gerardo ^b   Ilangumaran, Subburaj ^a   Saucier, Caroline ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MESSENGER RNA; PROTEIN P53; SCATTER FACTOR; SOCS1 PROTEIN, HUMAN; STAT1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING 1;

AGED; ANIMAL; CANCER GRADING; CANCER STAGING; CELL TRANSFORMATION; COLORECTAL TUMOR; DISEASE MODEL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; MOUSE; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UPREGULATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE GROWTH FACTOR; HUMANS; INTERFERON-GAMMA; MALE; MICE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING 1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84942280111     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep14301     Document Type: Article

References (50)

1. Elliott, J., Hookham, M. B. & Johnston, J. A. The suppressors of cytokine signalling E3 ligases behave as tumour suppressors. Biochem Soc Trans 36, 464-8 (2008).
2. Zhang, J., Li, H., Yu, J. P., Wang, S. E. & Ren, X. B. Role of SOCS1 in tumor progression and therapeutic application. Int J Cancer 130, 1971-80 (2012).
3. Inagaki-Ohara, K., Kondo, T., Ito, M. & Yoshimura, A. SOCS, infammation, and cancer. Jak-Stat 2, e24053 (2013).
4. Linossi, E. M., Babon, J. J., Hilton, D. J. & Nicholson, S. E. Suppression of cytokine signaling: The SOCS perspective. Cytokine Growth Factor Rev 24, 241-8 (2013).
5. Gui, Y. et al. Regulation of MET receptor signaling by SOCS1 and its implications for hepatocellular carcinoma. Curr Pharm Des 20, 2922-33 (2014).
6. Kazi, J. U., Kabir, N. N., Flores-Morales, A. & Ronnstrand, L. SOCS proteins in regulation of receptor tyrosine kinase signaling. Cell Mol Life Sci 71, 3297-310 (2014).
7. Yoshikawa, H. et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 28, 29-35 (2001).
8. Um, T. H. et al. Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis. J Hepatol 54, 939-47 (2011).
9. Nishida, N., Kudo, M., Nagasaka, T., Ikai, I. & Goel, A. Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. Hepatology 56, 994-1003 (2012).
10. Gui, Y. et al. SOCS1 controls liver regeneration by regulating HGF signaling in hepatocytes. J Hepatol 55, 1300-8 (2011).
11. Gui, Y. et al. Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma. Oncogene, doi: 10.1038/onc.2015.20 (2015).
12. Calabrese, V. et al. SOCS1 links cytokine signaling to p53 and senescence. Mol Cell 36, 754-67 (2009).
13. Raccurt, M. et al. Suppressor of cytokine signalling gene expression is elevated in breast carcinoma. Br J Cancer 89, 524-32 (2003).
14. Laner-Plamberger, S. et al. Hedgehog/GLI signaling activates suppressor of cytokine signaling 1 (SOCS1) in epidermal and neural tumor cells. PLoS One 8, e75317 (2013).
15. Li, Z. et al. Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. J Invest Dermatol 123, 737-45 (2004).
16. Scutti, J. A. et al. Role of SOCS-1 Gene on Melanoma Cell Growth and Tumor Development. Transl Oncol 4, 101-9 (2011).
17. Nosho, K. et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One 3, e3698 (2008).
18. Lee, S., Cho, N. Y., Yoo, E. J., Kim, J. H. & Kang, G. H. CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels. Arch Pathol Lab Med 132, 1657-65 (2008).
19. Ogino, S. et al. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J Mol Diagn 9, 305-14 (2007).
20. Ogino, S., Kawasaki, T., Kirkner, G. J., Loda, M. & Fuchs, C. S. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn 8, 582-8 (2006).
21. Samowitz, W. S. et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 129, 837-45 (2005).
22. David, M. et al. Suppressor of cytokine signaling 1 modulates invasion and metastatic potential of colorectal cancer cells. Molecular oncology 8, 942-55 (2014).
23. Ayyildiz, T., Dolar, E., Adim, S. B., Eminler, A. T. & Yerci, O. Lack of Prognostic Signifcance of SOCS-1 Expression in Colorectal Adenocarcinomas. Asian Pac J Cancer Prev 15, 8469-74 (2014).
24. Hanada, T. et al. IFNgamma-dependent, spontaneous development of colorectal carcinomas in SOCS1-defcient mice. J Exp Med 203, 1391-7 (2006).
25. Hashimoto, M. et al. Silencing of SOCS1 in macrophages suppresses tumor development by enhancing antitumor infammation. Cancer Sci 100, 730-6 (2009).
26. Shen, L., Evel-Kabler, K., Strube, R. & Chen, S. Y. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specifc anti-tumor immunity. Nat Biotechnol 22, 1546-53 (2004).
27. Cancer Genome Atlas, N. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-7 (2012).
28. Li, B. & Dewey, C. N. RSEM: accurate transcript quantifcation from RNA-Seq data with or without a reference genome. BMC bioinformatics 12, 323 (2011).
29. Brattain, M. G., Strobel-Stevens, J., Fine, D., Webb, M. & Sarrif, A. M. Establishment of mouse colonic carcinoma cell lines with diferent metastatic properties. Cancer Res 40, 2142-6 (1980).
30. Krebs, D. L. & Hilton, D. J. SOCS proteins: negative regulators of cytokine signaling. Stem Cells 19, 378-87 (2001).
31. Bernier, J., Chababi, W., Pomerleau, V. & Saucier, C. Oncogenic engagement of the Met receptor is sufcient to evoke angiogenic, tumorigenic, and metastatic activities in rat intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 299, G677-86 (2010).
32. Castle, J. C. et al. Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma. BMC Genomics 15, 190 (2014).
33. Lowe, S. W., Cepero, E. & Evan, G. Intrinsic tumour suppression. Nature 432, 307-15 (2004).
34. Luo, J. L., Maeda, S., Hsu, L. C., Yagita, H. & Karin, M. Inhibition of NF-kappaB in cancer cells converts infammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 6, 297-305 (2004).
35. Fojtova, M. et al. Development of IFN-gamma resistance is associated with attenuation of SOCS genes induction and constitutive expression of SOCS 3 in melanoma cells. Br J Cancer 97, 231-7 (2007).
36. Takahashi, Y. et al. Enhancement of antiproliferative activity of interferons by RNA interference-mediated silencing of SOCS gene expression in tumor cells. Cancer Sci 99, 1650-5 (2008).
37. Zitzmann, K. et al. SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells. Cancer Res 67, 5025-32 (2007).
38. Guenterberg, K. D. et al. Enhanced anti-tumor activity of interferon-alpha in SOCS1-defcient mice is mediated by CD4(+) and CD8(+) T cells. Cancer Immunol Immunother 60, 1281-8 (2011).
39. Ben-Zvi, T., Yayon, A., Gertler, A. & Monsonego-Ornan, E. Suppressors of cytokine signaling (SOCS) 1 and SOCS3 interact with and modulate fbroblast growth factor receptor signaling. Journal of cell science 119, 380-7 (2006).
40. Avalle, L., Pensa, S., Regis, G., Novelli, F. & Poli, V. STAT1 and STAT3 in tumorigenesis: A matter of balance. Jak-Stat 1, 65-72 (2012).
41. Klampfer, L. The role of signal transducers and activators of transcription in colon cancer. Front Biosci 13, 2888-99 (2008).
42. Gordziel, C., Bratsch, J., Moriggl, R., Knosel, T. & Friedrich, K. Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma. Br J Cancer 109, 138-46 (2013).
43. Stepanenko, A. A., Vassetzky, Y. S. & Kavsan, V. M. Antagonistic functional duality of cancer genes. Gene 529, 199-207 (2013).
44. Durbin, A. D., Hannigan, G. E. & Malkin, D. Oncogenic ILK, tumor suppression and all that JNK. Cell Cycle 8, 4060-6 (2009).
45. Musteanu, M. et al. Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice. Gastroenterology 138, 1003-11 e1-5 (2010).
46. Nguyen, A. V. et al. STAT3 in epithelial cells regulates infammation and tumor progression to malignant state in colon. Neoplasia 15, 998-1008 (2013).
47. Arends, J. W. Molecular interactions in the Vogelstein model of colorectal carcinoma. J Pathol 190, 412-6 (2000).
48. Pomerleau, V., Landry, M., Bernier, J., Vachon, P. H. & Saucier, C. Met receptor-induced Grb2 or Shc signals both promote transformation of intestinal epithelial cells, albeit they are required for distinct oncogenic functions. BMC Cancer 14, 240 (2014).
49. Mallette, F. A., Calabrese, V., Ilangumaran, S. & Ferbeyre, G. SOCS1, a novel interaction partner of p53 controlling oncogene-induced senescence. Aging (Albany NY) 2, 445-52 (2010).
50. Saucier, C. et al. The Shc adaptor protein is critical for VEGF induction by Met/HGF and ErbB2 receptors and for early onset of tumor angiogenesis. Proc Natl Acad Sci USA 101, 2345-50 (2004).